Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

被引：0
|
作者：
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
机构：
[1] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Division of Gastroenterology and Hepatolgy, CRC “A.M. and A.Migliavacca” Center for Liver Disease
[2] University of Milan,Department of Pathophysiology and Transplantation
[3] Center for HIV and Hepatogastroenterology,Internal Medicine and Hepatology Unit
[4] University of Salerno,Department of Life Sciences
[5] Glasgow Caledonian University,Department of Veterans Affairs
[6] Gastroenterology,Department of Gastroenterology and Hepatology
[7] Glasgow Royal Infirmary,Department of Gastroenterology, Hepatology and Endocrinology
[8] AbbVie Inc.,undefined
[9] AbbVie Deutschland GmBH Co. KG,undefined
[10] University of Liverpool Hepatology Drug Interactions Group,undefined
[11] VA Palo Alto Healthcare System,undefined
[12] Essen University Hospital,undefined
[13] Leberstiftungs-GmbH Deutschland,undefined
[14] Hannover Medical School,undefined
[15] Northwestern University Feinberg School of Medicine,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Fibrosis; Hepatitis C; Infectious disease; Review; Therapeutics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4033 / 4042
页数：9
相关论文
共 50 条
  • [11] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
    Mei Lu
    Loralee B. Rupp
    Christina Melkonian
    Sheri Trudeau
    Yihe G. Daida
    Mark A. Schmidt
    Stuart C. Gordon
    Advances in Therapy, 2024, 41 : 744 - 758
  • [12] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naive patients with compensated cirrhosis: real-world experience from Taiwan HCV registry
    Hung, Chao-Hung
    Chang, Te-Sheng
    Huang, Chung-Feng
    Kuo, Hsing-Tao
    Lo, Ching-Chu
    Huang, Chien-Wei
    Chong, Lee-Won
    Cheng, Pin-Nan
    Yeh, Ming-Lun
    Peng, Cheng-Yuan
    Cheng, Chien-Yu
    Huang, Jee-Fu
    Bair, Ming-Jong
    Lin, Chih-Lang
    Yang, Chi-Chieh
    Wang, Sih-Ren
    Hsieh, Tsai-Yuan
    Lee, Tzong-Hsi
    Lee, Pei-Lun
    Wu, Wen-Chih
    Lin, Chih-Lin
    Su, Wei-Wen
    Yang, Shengshun
    Wang, Chia-Chi
    Hu, Jui-Ting
    Mou, Lien-Juei
    Chen, Chun-Ting
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Huang, Jia-Sheng
    Chen, Guei-Ying
    Gao, Jian-Neng
    Tai, Chi-Ming
    Liu, Chun-Jen
    Lee, Mei-Hsuan
    Tsai, Pei-Chien
    Dai, Chia-Yen
    Kao, Jia-Horng
    Lin, Han-Chieh
    Chuang, Wan-Long
    Chen, Chiyi
    Tseng, Kuo-Chih
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2022, 77 : S595 - S596
  • [13] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
    Chang, Te-Sheng
    Huang, Chung-Feng
    Kuo, Hsing-Tao
    Lo, Ching-Chu
    Huang, Chien-Wei
    Chong, Lee-Won
    Cheng, Pin-Nan
    Yeh, Ming-Lun
    Peng, Cheng-Yuan
    Cheng, Chien-Yu
    Huang, Jee-Fu
    Bair, Ming-Jong
    Lin, Chih-Lang
    Yang, Chi-Chieh
    Wang, Szu-Jen
    Hsieh, Tsai-Yuan
    Lee, Tzong-Hsi
    Lee, Pei-Lun
    Wu, Wen-Chih
    Lin, Chih-Lin
    Su, Wei-Wen
    Yang, Sheng-Shun
    Wang, Chia-Chi
    Hu, Jui-Ting
    Mo, Lein-Ray
    Chen, Chun-Ting
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Huang, Chia-Sheng
    Chen, Guei-Ying
    Kao, Chien-Neng
    Tai, Chi-Ming
    Liu, Chun-Jen
    Lee, Mei-Hsuan
    Tsai, Pei-Chien
    Dai, Chia-Yen
    Kao, Jia-Horng
    Lin, Han-Chieh
    Chuang, Wang-Long
    Chen, Chi-Yi
    Tseng, Kuo-Chih
    Hung, Chao-Hung
    Yu, Ming-Lung
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 550 - 561
  • [14] Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
    Markus Cornberg
    Adriana Ahumada
    Alessio Aghemo
    Massimo Andreoni
    Abhi Bhagat
    Isabel Butrymowicz
    Michal Carmiel
    Gabriel Chodick
    Brian Conway
    Yanna Song
    Antonio Gasbarrini
    Dietrich Hüppe
    Francisco Jorquera Plaza
    Pietro Lampertico
    Maria Luisa Manzano Alonso
    Lindsay Myles
    Marcello Persico
    Alnoor Ramji
    Christoph Sarrazin
    Erica Villa
    Clara Weil
    Juan Isidro Uriz Otano
    Advances in Therapy, 2022, 39 : 3146 - 3158
  • [15] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis (vol 41, pg 744, 2024)
    Lu, Mei
    Rupp, Loralee B.
    Melkonian, Christina
    Trudeau, Sheri
    Daida, Yihe G.
    Schmidt, Mark A.
    Gordon, Stuart C.
    ADVANCES IN THERAPY, 2024, 41 (06) : 2534 - 2535
  • [16] Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarebska-Michaluk, Dorota
    Jaroszewicz, Jerzy
    Pabjan, Pawel
    Lapinski, Tadeusz W.
    Mazur, Wlodzimierz
    Krygier, Rafal
    Dybowska, Dorota
    Halota, Waldemar
    Pawlowska, Malgorzata
    Janczewska, Ewa
    Buczynska, Iwona
    Simon, Krzysztof
    Dobracka, Beata
    Citko, Jolanta
    Laurans, Lukasz
    Tudrujek-Zdunek, Magdalena
    Tomasiewicz, Krzysztof
    Piekarska, Anna
    Sitko, Marek
    Bialkowska-Warzecha, Jolanta
    Klapaczynski, Jakub
    Sobala-Szczygiel, Barbara
    Horban, Andrzej
    Berak, Hanna
    Deron, Zbigniew
    Lorenc, Beata
    Socha, Lukasz
    Tronina, Olga
    Flisiak, Robert
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (07) : 1944 - 1952
  • [17] Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naive patients from Taiwan nationwide HCV registry
    Huang, Chung-Feng
    Chang, Te-Sheng
    Kuo, Hsing-Tao
    Huang, Chien-Wei
    Mo, Lien-Ray
    Tai, Chi-Ming
    Tseng, Kuo-Chih
    Bair, Ming-Jong
    Wang, Sih-Ren
    Lo, Ching-Chu
    Chong, Lee-Won
    Cheng, Pin-Nan
    Yeh, Ming-Lun
    Peng, Cheng-Yuan
    Cheng, Chien-Yu
    Huang, Jee-Fu
    Lin, Chih-Lang
    Yang, Chi-Chieh
    Hsieh, Tsai-Yuan
    Lee, Tzong-Hsi
    Lee, Pei-Lun
    Wu, Wen-Chih
    Lin, Chih-Lin
    Su, Wei-Wen
    Yang, Sheng-Shun
    Wang, Chia-Chi
    Hu, Jui-Ting
    Chen, Chun-Ting
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Huang, Chia-Sheng
    Chen, Guei-Ying
    Kao, Chien-Neng
    Liu, Chun-Jen
    Lee, Mei-Hsuan
    Tsai, Pei-Chien
    Dai, Chia-Yen
    Kao, Jia-Horng
    Lin, Han-Chieh
    Chuang, Wan-Long
    Hung, Chao-Hung
    Chen, Chi-Yi
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2024, 80 : S832 - S833
  • [18] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
    Flamm, Steven L.
    Kort, Jens
    Marx, Steven E.
    Strezewski, John
    Dylla, Douglas E.
    Bacon, Bruce
    Curry, Michael P.
    Tsai, Naoky
    Wick, Nicole
    ADVANCES IN THERAPY, 2020, 37 (05) : 2267 - 2274
  • [19] Eight-week glecaprevir/pibrentasvir in Canadian hepatitis C virus-infected, treatment-naïve, compensated cirrhotic people: CREST study
    Conway, Brian
    Cooper, Curtis
    Gaertner, Roger
    Gandhi, Veeral
    Haider, Shariq
    Myles, Lindsay
    Stewart, Kris
    Wong, Alexander
    Ramji, Alnoor
    FUTURE VIROLOGY, 2024, 19 (10-11) : 361 - 370
  • [20] Comparison of 8-versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
    Lu, Yung-Hsin
    Lu, Chung-Kuang
    Chen, Chun-Hsien
    Hsieh, Yung-Yu
    Tung, Shui-Yi
    Chen, Yi-Hsing
    Yen, Chih-Wei
    Tung, Wei-Lin
    Chang, Kao-Chi
    Chen, Wei-Ming
    Lu, Sheng-Nan
    Hung, Chao-Hung
    Chang, Te-Sheng
    PLOS ONE, 2022, 17 (08):
12345